PE20241998A1 - Anticuerpos anti-calreticulina (calr) mutante y usos de estos - Google Patents

Anticuerpos anti-calreticulina (calr) mutante y usos de estos

Info

Publication number
PE20241998A1
PE20241998A1 PE2024001321A PE2024001321A PE20241998A1 PE 20241998 A1 PE20241998 A1 PE 20241998A1 PE 2024001321 A PE2024001321 A PE 2024001321A PE 2024001321 A PE2024001321 A PE 2024001321A PE 20241998 A1 PE20241998 A1 PE 20241998A1
Authority
PE
Peru
Prior art keywords
antibodies
calreticulin
calr
mutant anti
mutcalr
Prior art date
Application number
PE2024001321A
Other languages
English (en)
Spanish (es)
Inventor
Patrick Mayes
Horacio G Nastri
Rebecca A Buonpane
Edimara S Reis
Shaun M Stewart
Jing Zhou
Marc C Deller
Hsiang-Ting Lei
Leslie Brooke Epling Mcquirter
Yonghong Zhao
Hamza Celik
Brittney Melissa Wass
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of PE20241998A1 publication Critical patent/PE20241998A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PE2024001321A 2021-12-08 2022-12-07 Anticuerpos anti-calreticulina (calr) mutante y usos de estos PE20241998A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163287394P 2021-12-08 2021-12-08
US202163288479P 2021-12-10 2021-12-10
US202263421052P 2022-10-31 2022-10-31
PCT/US2022/081076 WO2023107994A1 (en) 2021-12-08 2022-12-07 Anti-mutant calreticulin (calr) antibodies and uses thereof

Publications (1)

Publication Number Publication Date
PE20241998A1 true PE20241998A1 (es) 2024-09-27

Family

ID=84943209

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2024001321A PE20241998A1 (es) 2021-12-08 2022-12-07 Anticuerpos anti-calreticulina (calr) mutante y usos de estos

Country Status (19)

Country Link
US (1) US20230272055A1 (https=)
EP (1) EP4444343A1 (https=)
JP (1) JP2025500796A (https=)
KR (1) KR20240127992A (https=)
AU (1) AU2022407445A1 (https=)
CA (1) CA3241889A1 (https=)
CL (2) CL2024001654A1 (https=)
CO (1) CO2024009042A2 (https=)
CR (1) CR20240277A (https=)
DO (1) DOP2024000110A (https=)
GE (1) GEAP202416555A (https=)
IL (1) IL313366A (https=)
JO (1) JOP20240122A1 (https=)
MX (1) MX2024006954A (https=)
PE (1) PE20241998A1 (https=)
TW (1) TW202330623A (https=)
UY (1) UY40062A (https=)
WO (1) WO2023107994A1 (https=)
ZA (1) ZA202404295B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117467004B (zh) * 2023-10-09 2024-06-21 武汉爱博泰克生物科技有限公司 抗人钙网膜蛋白的兔单克隆抗体及其应用
WO2025096716A1 (en) * 2023-11-01 2025-05-08 Incyte Corporation Anti-mutant calreticulin (calr) antibody-drug conjugates and uses thereof
WO2026013015A1 (en) * 2024-07-09 2026-01-15 Merus N.V. Multispecific binding moieties comprising calr and cd3 binding domains

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
KR101763656B1 (ko) 2009-06-29 2017-08-01 인사이트 홀딩스 코포레이션 Ｐｉ3ｋ 저해물질로서의 피리미디논
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
CN103797010B (zh) 2011-06-20 2016-02-24 因塞特控股公司 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
TWI646099B (zh) 2012-11-01 2019-01-01 英塞特控股公司 作爲ｊａｋ抑制劑之三環稠合噻吩衍生物
WO2016087514A1 (en) 2014-12-02 2016-06-09 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
SG11202108494YA (en) * 2019-02-28 2021-09-29 Juntendo Educational Found Antibodies that bind to cleaved form of mutant calreticulin, and diagnostic, preventive, or therapeutic agent for myeloproliferative neoplasm

Also Published As

Publication number Publication date
DOP2024000110A (es) 2024-09-30
GEAP202416555A (en) 2024-10-28
ZA202404295B (en) 2025-02-26
MX2024006954A (es) 2024-06-21
IL313366A (en) 2024-08-01
TW202330623A (zh) 2023-08-01
JP2025500796A (ja) 2025-01-15
KR20240127992A (ko) 2024-08-23
UY40062A (es) 2023-06-30
CO2024009042A2 (es) 2024-08-08
CL2025000229A1 (es) 2025-06-06
EP4444343A1 (en) 2024-10-16
CR20240277A (es) 2024-08-07
AU2022407445A1 (en) 2024-06-13
US20230272055A1 (en) 2023-08-31
CA3241889A1 (en) 2023-06-15
JOP20240122A1 (ar) 2024-05-29
WO2023107994A1 (en) 2023-06-15
CL2024001654A1 (es) 2024-11-04

Similar Documents

Publication Publication Date Title
CL2025000229A1 (es) Anticuerpos anti-calreticulina (calr) mutante y usos de estos
BR112021026376A2 (pt) Proteínas de fusão flt3l-fc e métodos de uso
CO2022009248A2 (es) Anticuerpos anti-cd73 y usos de estos
CL2021003191A1 (es) Inhibidores de tead y usos de los mismos
MX2021014443A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
CL2023001492A1 (es) Anticuerpos anti-ly6g6d y métodos de uso.
MX2020012765A (es) Métodos y compuestos de ácido nucleico modificado con lípidos.
EA201992001A1 (ru) Композиции и способы повышения экспрессии генов
CO2022004797A2 (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5/klk7 y métodos de uso
CL2021002656A1 (es) Compuestos de pirrolotriazina, inhibidores selectivos de proteínas quinasas kit y pdgfralfa; composición y uso.
MX2021015301A (es) Métodos de cultivo celular y composiciones para la producción de anticuerpos.
MX2021011609A (es) Moduladores de interacciones de proteinas de superficie celular y metodos y composiciones relacionados con estos.
MX2021012692A (es) Anticuerpos anti-mertk y sus metodos de uso.
BR112022005330A2 (pt) Organismos semissintéticos eucarióticos
CO2022006014A2 (es) Terapia de tumores sólidos cd70+ utilizando linfocitos t genomodificados dirigidos a cd70 referencia cruzada a solicitudes relacionadas
BR112023018948A2 (pt) Edição multiplex com enzimas cas
MX2020011470A (es) Metodos de terapia genica.
CL2019000682A1 (es) Identificación y aislamiento del progenitor ótico humano.
CL2023003151A1 (es) Anticuerpos anti-notch2 y métodos de uso
MX2021012649A (es) Medio de cultivo celular para celulas eucarioticas.
AR127891A1 (es) Anticuerpos anti-calreticulina (calr) mutante y usos de estos
AR110908A1 (es) Constructo promotor para la síntesis de proteínas libre de células
MX2020004539A (es) Polipeptidos de caspasa-9 modificados y sus metodos de uso.
AR119269A1 (es) Métodos y composiciones de cultivo celular para producción de anticuerpos